Efficacy and Safety of Wuling San on Breast Cancer-related Lymphedema

Inclusion Criteria: * Women completed all primary and adjuvant treatments (surgery, chemotherapy, radiotherapy) * age 20-40 with unilateral BCRL, stage I or II, BMI of 18-25 * Volume difference ≥300 mL between the normal and lymphedematous upper extremity based on perometry evaluation * No evidence of breast cancer recurrence * At least 6 months postoperative from axillary lymph node dissection Exclusion Criteria: * Bilateral lymphedema or stage III lymphedema * History of bilateral axillary lymph node dissection * Recent history of cellulitis in the affected extremity (within last 3 months) * Recurrent breast cancer or other malignancy * Current (within last month) use of chemotherapy for breast or other malignancy * Current (within last 3 months) use of radiation for breast or other malignancy * Recent (within last month) or current intensive MLD and/or short stretch bandage use * Unstable lymphedema (i.e. worsening symptoms/measurements in the past 3 months) * Pregnant or nursing (lactating) women * Patients that take drugs like diosmin at the time of enrollment, or within 30 days. * Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer. * Unable to comply with the protocol, measurement and follow-up schedule.